You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to April 2024

AbstractFullPdf
Oct 20221209
Nov 20225607
Dec 202261010
Jan 20233803
Feb 20232704
Mar 20234005
Apr 20235404
May 202346015
Jun 202341013
Jul 20234405
Aug 20233605
Sep 202367010
Oct 20233904
Nov 20237008
Dec 20234703
Jan 2024801
Feb 20245204
Mar 20244008
Apr 2024400
Total7820118